Whitehawk Therapeutics, Inc.
WHWK- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001422142
No open-market purchases or sales by Whitehawk Therapeutics, Inc. insiders were filed in the last 90 days; 77 institutions reported holding it in 13F filings for Q2 2026, worth $198.0M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +16 vs. previous quarter
- 77
- 13F valueReported value at the end of Q2 2026
- $198.0M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding WHWK, Q2 2026
No superinvestor reported holding WHWK at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Whitehawk Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Apr 17, 2026 (view filing) | Apr 15-16 | 2 days | Giacobello Scott M.CHIEF FINANCIAL OFFICER | SSale | −218.6K | $4.03 | −$882.0K | −42.5%295.2K after | 2 lots |
| Apr 15, 2026 (view filing) | Apr 13-14 | 2 days | Ball BryanSee remarks | SSale | −118.8K | $3.60 | −$427.9K | −23.0%397.1K after | 2 lots |
| Apr 13, 2026 (view filing) | Apr 9-10 | 4 days | Ball BryanSee remarks | SSale | −56.6K | $3.55 | −$201.1K | −9.9%516.0K after | 2 lots |
| Apr 10, 2026 (view filing) | Apr 9 | 1 day | Lennon David JamesCHIEF EXECUTIVE OFFICER | SSale | −14.5K | $3.38 | −$49.0K | −2.7%518.6K after | |
| Apr 8, 2026 (view filing) | Apr 6-8 | 2 days | Lennon David JamesCHIEF EXECUTIVE OFFICER | SSale | −260.4K | $3.45 | −$899.5K | −32.8%533.1K after | 3 lots |
| Apr 3, 2026 (view filing) | Apr 2 | 1 day | Lennon David JamesCHIEF EXECUTIVE OFFICER | SSale | −26.9K | $3.48 | −$93.5K | −3.3%793.5K after | |
| Mar 10, 2026 (view filing) | Mar 2 | 8 daysLate | Lennon David JamesCHIEF EXECUTIVE OFFICER | SSale | −5.10K | $3.31 | −$16.9K | −10.3%44.6K after | |
| Mar 10, 2026 (view filing) | Mar 2 | 8 daysLate | Ball BryanSee remarks | SSale | −1.83K | $3.31 | −$6.07K | −0.9%206.0K after | |
| Mar 10, 2026 (view filing) | Mar 2 | 8 daysLate | Giacobello Scott M.CHIEF FINANCIAL OFFICER | SSale | −2.59K | $3.31 | −$8.59K | −8.5%28.1K after | |
| Mar 4, 2025 (view filing) | Mar 3 | 1 day | Ball BryanSee remarks | SSale | −2.15K | $2.35 | −$5.05K | −2.0%102.9K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Whitehawk Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Fan Yu | 4,861,314 | $22.3M | 20.63% | +2,791,314+134.8% | Added |
| Acuta Capital Partners, LLC | 4,685,912 | $21.5M | 14.96% | +1,275,510+37.4% | Added |
| QVT Financial LP | 4,615,709 | $21.1M | 1.35% | 00.0% | Unchanged |
| Suvretta Capital Management, LLC | 4,300,000 | $19.7M | 0.41% | +600,000+16.2% | Added |
| OrbiMed Advisors LLC | 3,934,296 | $18.0M | 0.34% | −231,704−5.6% | Reduced |
| Avoro Capital Advisors LLC | 2,849,402 | $13.1M | 0.12% | 00.0% | Unchanged |
| Siren, L.L.C. | 2,337,102 | $10.7M | 0.22% | +255,102+12.3% | Added |
| KVP Capital Advisors, LP | 2,165,997 | $9.92M | 7.28% | 00.0% | Unchanged |
| BlackRock, Inc. | 1,922,828 | $8.81M | 0.00% | +1,571,443+447.2% | Added |
| Vanguard Capital Management LLC | 1,388,561 | $6.36M | 0.00% | +72,791+5.5% | Added |